Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
AstraZeneca
Johnson and Johnson
McKinsey
Dow

Last Updated: August 19, 2022

ZIPSOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Zipsor patents expire, and when can generic versions of Zipsor launch?

Zipsor is a drug marketed by Assertio and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZIPSOR is diclofenac potassium. There are forty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zipsor

A generic version of ZIPSOR was approved as diclofenac potassium by TEVA on August 6th, 1998.

  Try it Free

Drug patent expirations by year for ZIPSOR
Drug Prices for ZIPSOR

See drug prices for ZIPSOR

Drug Sales Revenue Trends for ZIPSOR

See drug sales revenues for ZIPSOR

Paragraph IV (Patent) Challenges for ZIPSOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZIPSOR Capsules diclofenac potassium 25 mg 022202 1 2012-11-14

US Patents and Regulatory Information for ZIPSOR

ZIPSOR is protected by six US patents and one FDA Regulatory Exclusivity.

Patents protecting ZIPSOR

Method of treating post-surgical acute pain
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Method of treating post-surgical acute pain
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Method of treating post-surgical acute pain
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Method of treating post-surgical acute pain
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Method of treating post-surgical acute pain
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Method of treating post-surgical acute pain
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

FDA Regulatory Exclusivity protecting ZIPSOR

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZIPSOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 See Plans and Pricing See Plans and Pricing
Assertio ZIPSOR diclofenac potassium CAPSULE;ORAL 022202-001 Jun 16, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZIPSOR

See the table below for patents covering ZIPSOR around the world.

Country Patent Number Title Estimated Expiration
Slovakia 572002 PHARMACEUTICAL COMPOSITION, METHOD FOR THE PREPARATION THEREOF AND ITS USE See Plans and Pricing
Norway 20003698 See Plans and Pricing
Germany 69940769 See Plans and Pricing
South Africa 200200741 Oral liquid compositions. See Plans and Pricing
Mexico PA02000583 COMPOSICIONES LIQUIDAS ORALES. (ORAL LIQUID COMPOSITIONS.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Harvard Business School
Dow
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.